ZLAB: Diversified Pipeline And DLL3 Partnerships Will Support Long-Term Expansion

The analyst price target for Zai Lab has been reduced by about $14 to $35, with analysts citing lower modeled revenue growth, modestly higher discount rates, and management's commentary on more modest 2026 top line expectations given pricing pressures and competition in China.

Analyst Commentary

Recent Street research on Zai Lab points to a more cautious stance on revenue growth and valuation, with several firms trimming their price targets while still recognizing areas of execution strength and pipeline potential.

Bullish Takeaways

Bullish analysts who maintain positive ratings argue that the current valuation already reflects many of the near term headwinds, leaving room if management hits its updated revenue and margin assumptions.
Full year revenue of US$460.2m, in line with consensus, is viewed as evidence that the business can meet externally set expectations, which supports confidence in management's ability to execute on guidance.
Some analysts highlight that price target cuts, such as the moves to US$53 and then US$47, are framed as model recalibrations rather than a shift to negative views on the underlying business, with Buy ratings kept in place.
JPMorgan coverage and ongoing interest from large global banks are seen as a sign that Zai Lab remains relevant in institutional portfolios, which can help support liquidity and shareholder engagement over time.

Bearish Takeaways

Bearish analysts are focused on management's own indication that 2026 top line growth is likely to be modest, which feeds directly into lower long term revenue curves and, in turn, lower price targets.
Weaker than expected Vyvgart sales in the recent period have raised questions about the pace of uptake for certain key products, leading to more conservative assumptions around future contribution from that franchise.
Pricing pressures and competition in China are key concerns, as they may limit Zai Lab's ability to expand margins or raise prices, which weighs on profitability assumptions and justifies higher discount rates.
The series of price target reductions, including cuts from US$58 to US$53, then to US$47, and moves to levels such as US$37, signal that analysts are building in more cautious long term growth and risk profiles in their valuation work.

What's in the News

Zai Lab reported new preclinical data for ZL-1503, an internally developed IL-13/IL-31Ra bispecific antibody, showing sustained suppression of itch and inflammation in atopic disease models and supporting ongoing global Phase 1/1b trials in moderate to severe atopic dermatitis. (Key Developments)
Clinical data for zocilurtatug pelitecan (zoci, formerly ZL-1310), a DLL3-targeting ADC, indicated rapid intracranial responses and tumor size reductions in patients with extensive stage small cell lung cancer and brain metastases, along with activity in other neuroendocrine carcinomas, with a reported intracranial objective response rate of 53.7% in a subset of patients. (Key Developments)
Boehringer Ingelheim and Zai Lab entered a clinical collaboration to test a dual DLL3-targeting regimen that combines obrixtamig, a DLL3/CD3 T cell engager, with Zai Lab’s zoci in a Phase Ib/II study in small cell lung cancer and other neuroendocrine carcinomas. (Key Developments)
Zai Lab announced a global clinical trial collaboration with Amgen to evaluate zoci in combination with Amgen’s IMDELLTRA, a DLL3-targeting Bispecific T cell Engager therapy, in a global Phase 1b study in patients with extensive stage small cell lung cancer. (Key Developments)
The company highlighted that three internally developed oncology programs, including zoci, ZL-6201, and ZL-1222, will be featured in four poster sessions at the AACR Annual Meeting 2026 in San Diego, covering early clinical and discovery data across multiple solid tumor indications. (Key Developments)

Valuation Changes

Fair Value was cut from $49.49 to $35.34, reflecting a substantial reduction in modeled upside.
The Discount Rate edged up slightly from 7.70% to 7.89%, indicating a modestly higher required return in the model.
Revenue Growth was reduced in the model from 38.33% to 19.95%, roughly halving the prior long-term growth assumption.
Net Profit Margin was adjusted slightly higher from 12.47% to 12.77%, signaling a small improvement in long-run profitability assumptions.
Future P/E was held broadly steady, moving marginally from 50.90x to 51.20x, suggesting little change in the earnings multiple used.

7 views

Key Takeaways

Robust product pipeline and operational improvements are set to diversify revenue and increase profitability through expanded market access and AI-driven cost efficiencies.
Growing demand for innovative therapies and supportive regulatory conditions are expected to accelerate volume growth, market penetration, and long-term sales.
Dependence on external innovation, competitive pressure, regulatory hurdles, and geopolitical risks threaten margins, market share, and international growth despite aggressive spending and pipeline renewal efforts.

Catalysts

About Zai Lab

A biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases.What are the underlying business or industry changes driving this perspective?

Multiple high-potential product launches and label expansions over the next 12-18 months (including VYVGART, bemarituzumab, KarXT, TIVDAK, Tumor Treating Fields), combined with a deep pipeline in oncology and immunology, are expected to significantly increase Zai Lab's addressable market and diversify revenue streams, supporting both top-line growth and future earnings.
Rising healthcare spending and rapid adoption of innovative therapies in China, coupled with new treatment guidelines (e.g., VYVGART for gMG) and expanded reimbursement channels (including anticipated NRDL listings and growing commercial insurance), are expected to drive strong volume and broader market penetration, accelerating revenue growth and boosting long-term sales potential.
Ongoing operational efficiencies-such as localizing manufacturing, resource-efficient sales force redeployment, and AI-driven cost optimization-are forecasted to yield margin expansion, reducing SG&A and R&D expenses as a percentage of revenue, thus improving profitability and long-term net margins.
The maturing population in China and globally is expected to fuel sustained demand for innovative chronic and complex disease treatments (e.g., in oncology and autoimmunity), creating a large and expanding patient pool that will underpin durable revenue growth for Zai Lab's existing and upcoming therapies.
Improved clinical and regulatory execution (e.g., multiple ongoing pivotal trials, FDA Fast Track/Orphan Drug designations, and anticipated accelerated approvals both in China and globally) positions Zai Lab to bring therapies to market faster, reducing time-to-revenue and supporting a long-term positive earnings trajectory.

Zai Lab Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Zai Lab's revenue will grow by 19.9% annually over the next 3 years.
Analysts are not forecasting that Zai Lab will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Zai Lab's profit margin will increase from -38.1% to the average US Biotechs industry of 12.8% in 3 years.
If Zai Lab's profit margin were to converge on the industry average, you could expect earnings to reach $101.4 million (and earnings per share of $0.86) by about May 2029, up from -$175.5 million today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 51.4x on those 2029 earnings, up from -13.9x today. This future PE is greater than the current PE for the US Biotechs industry at 16.3x.
Analysts expect the number of shares outstanding to grow by 2.0% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.89%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Heavy reliance on externally sourced innovation and in-licensing (as indicated by a focus on partnerships and externally sourced pipeline assets) exposes Zai Lab to persistent royalty and milestone payments, which may structurally limit long-term net margins even as top-line revenue grows.
Intensifying competition in China's oncology and immunology markets from both domestic biotech firms and multinational pharma (highlighted by ZEJULA's "softer quarter" and the upcoming launch of competitors like Lynparza generics) may erode Zai Lab's first-mover advantage, threaten future market share, and constrain revenue growth from its current portfolio.
Regulatory and pricing uncertainty in China, including the NRDL listing process, drug price reforms, and the time lag between product approvals and reimbursement, could delay revenue recognition from newly launched drugs (like bema and VYVGART new indications), depress achievable prices, and compress future profit margins.
Sustained high R&D and SG&A spend, ongoing need for "pipeline renewal," and limited blockbuster opportunities in the near term may keep Zai Lab's earnings under pressure and lengthen the timeline to durable profitability, despite guidance for an adjusted break-even in Q4 2025.
Geopolitical risks and expanding trade barriers between China and Western markets threaten cross-border partnerships, regulatory pathways for global trials, and Zai Lab's stated "bridge" strategy-potentially slowing its ability to access new therapeutics and limiting growth in international revenue streams that underpin long-term earnings potential.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $35.34 for Zai Lab based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $53.0, and the most bearish reporting a price target of just $24.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $794.1 million, earnings will come to $101.4 million, and it would be trading on a PE ratio of 51.4x, assuming you use a discount rate of 7.9%.
Given the current share price of $21.64, the analyst price target of $35.34 is 38.8% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Zai Lab?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Expanding China Healthcare And Global Pipelines Will Broaden Patient Options